“List of antidepressants”的意思、由来-开放百科全书

This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for major depressive disorder unless noted otherwise.

Selective serotonin reuptake inhibitors (SSRIs)

Serotonin–norepinephrine reuptake inhibitors (SNRIs)

Serotonin modulator and stimulators (SMSs)

Serotonin antagonist and reuptake inhibitors (SARIs)

Norepinephrine reuptake inhibitors (NRIs)

Although marketed as an antidepressant, a meta-analysis found that reboxetine was ineffective and potentially harmful.^[1]

Norepinephrine–dopamine reuptake inhibitors (NDRIs)

Tricyclic antidepressants (TCAs)

Tetracyclic antidepressants (TeCAs)

Mianserin, mirtazapine, and setiptiline are also sometimes described as noradrenergic and specific serotonergic antidepressants (NaSSAs).

Monoamine oxidase inhibitors (MAOIs)

Irreversible

Non-selective

Selective for MAO-B

Reversible

Non-selective

Caroxazone (Surodil, Timostenil) was formerly used as an antidepressant, but has been discontinued.

Selective for MAO-A

These drugs are sometimes described as reversible inhibitors of MAO-A (RIMAs).

Eprobemide (Befol) and minaprine (Brantur, Cantor) were also formerly used as antidepressants, but have been discontinued.

Mixed

Non-selective

Others

Marketed

Discontinued/withdrawn

Over-the-counter

The following antidepressants are available both with a prescription and over-the-counter:

Adjunctive treatments

Atypical antipsychotics

Others

Combination products

See also

References

1. ^{{cite journal | vauthors = Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B | title = Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials | journal = BMJ | volume = 341 | issue = | pages = c4737 | year = 2010 | pmid = 20940209 | pmc = 2954275 | doi = 10.1136/bmj.c4737| url = }}
2. ^{{cite journal | vauthors = Arias HR, Santamaría A, Ali SF | title = Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion | journal = Int. Rev. Neurobiol. | volume = 88 | issue = | pages = 223–55 | year = 2009 | pmid = 19897080 | doi = 10.1016/S0074-7742(09)88009-4 | url = | series = International Review of Neurobiology | isbn = 9780123745040 }}
3. ^{{cite web | title = SPRAVATO™ (esketamine) nasal spray FDA label | publisher = Food and Drug Administration | date = 5 March 2019 | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf | format = PDF | accessdate = 6 March 2019}}
4. ^{{cite journal | vauthors = Zhang MW, Harris KM, Ho RC | title = Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications | journal = BMC Med Ethics | volume = 17 | issue = | pages = 4 | year = 2016 | pmid = 26768892 | pmc = 4714497 | doi = 10.1186/s12910-016-0087-3 | url = }}
5. ^{{cite book|author1=Gian F. Placidi|author2=Liliana Dell'Osso|author3=Giuseppe Nistico |author4=Hagop S. Akiskal|title=Recurrent Mood Disorders: New Perspectives in Therapy|url=https://books.google.com/books?id=pIvcBQAAQBAJ&pg=PT293|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-76646-6|pages=293–}}
6. ^{{cite journal | vauthors = Thase ME | title = Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits? | journal = Psychiatr. Clin. North Am. | volume = 39 | issue = 3 | pages = 477–86 | year = 2016 | pmid = 27514300 | doi = 10.1016/j.psc.2016.04.008 | url = }}